<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">34425873</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-6215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Trials</Title>
          <ISOAbbreviation>Trials</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.</ArticleTitle>
        <Pagination>
          <StartPage>561</StartPage>
          <MedlinePgn>561</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">561</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05538-5</ELocationID>
        <Abstract>
          <AbstractText>A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Here, we report an unprecedented collaboration between sponsor, contract research organization (CRO), and regulatory authorities that enabled accelerated generation of these phase I data, including administration of the first-in-human (FIH) dose of molnupiravir within 5 days of receiving regulatory approval in the United Kingdom (UK). Single and multiple ascending dose (SAD and MAD, respectively) cohorts were dosed in randomized, double-blind, and placebo-controlled fashion, with a 6:2 active-to-placebo ratio in each cohort. A food-effect (FE) cohort included 10 subjects who were randomized to receive drug in the fasted or fed state followed by the fed or fasted state to complete a fed and fasted sequence for each subject. Dose escalation decisions were accelerated and MAD cohorts were initiated prior to completion of all SAD cohorts with the provision that the total daily dose in a MAD cohort would not exceed a dose proven to be safe and well-tolerated in a SAD cohort. Dosing in healthy volunteers was completed for eight single ascending dose (SAD) cohorts, seven multiple ascending dose (MAD) cohorts, and one food-effect (FE) cohort within approximately 16 weeks of initial protocol submission to the Research Ethics Committee (REC) and Medicines and Healthcare products Regulatory Agency (MHRA). Working to standard industry timelines, the FIH study would have taken approximately 46 weeks to complete and 33 weeks to enable phase 2 dosing. Data from this study supported submission of a phase 2/3 clinical trial protocol to the US Food and Drug Administration (FDA) within 8 weeks of initial protocol submission, with FDA comments permitting phase 2 study initiation within two additional weeks. In the setting of a global pandemic, this model of collaboration allows for accelerated generation of clinical data compared to standard processes, without compromising safety.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Holman</LastName>
            <ForeName>Wendy</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics, 3480 Main Highway, Unit 402, Miami, FL, 33133, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holman</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics, 3480 Main Highway, Unit 402, Miami, FL, 33133, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McIntosh</LastName>
            <ForeName>Stacy</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics, 3480 Main Highway, Unit 402, Miami, FL, 33133, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>Wendy</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Emory University School of Medicine, Drug Innovations at Emory (DRIVE) and Emory Institute of Drug Development (EIDD), 954 Gatewood Road, Atlanta, GA, 30329, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Emory University School of Medicine, Drug Innovations at Emory (DRIVE) and Emory Institute of Drug Development (EIDD), 954 Gatewood Road, Atlanta, GA, 30329, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bush</LastName>
            <ForeName>Jim</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds, LS2 9LH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Oren</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0002-6835-3473</Identifier>
            <AffiliationInfo>
              <Affiliation>Covance, Inc., 6 Drive, Research Triangle Park, Moore, NC, 27709, USA. oren.cohen@covance.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Trials</MedlineTA>
        <NlmUniqueID>101263253</NlmUniqueID>
        <ISSNLinking>1745-6215</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012263">Ribonucleosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012263" MajorTopicYN="Y">Ribonucleosides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Accelerated start-up</Keyword>
        <Keyword MajorTopicYN="N">Antiviral therapy</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Phase I</Keyword>
        <Keyword MajorTopicYN="N">Ribonucleoside analog</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>Wendy Holman, Wayne Homan, Stacy McIntosh, and Wendy Painter are employees of Ridgeback Biotherapeutics, which funded the study. George Painter holds a number of patents that are relevant to EIDD-2801 (molnupiravir)—see separately submitted ICMJE form. Jim Bush and Oren Cohen are employees of Covance, the CRO chosen by Ridgeback to assist in the execution of the study described.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34425873</ArticleId>
        <ArticleId IdType="pmc">PMC8380870</ArticleId>
        <ArticleId IdType="doi">10.1186/s13063-021-05538-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s13063-021-05538-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chan JF, Yuan S, Kok KH, To KKW. Chu H, Yang J, et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30154-9</ArticleId>
            <ArticleId IdType="pmc">PMC7159286</ArticleId>
            <ArticleId IdType="pubmed">31986261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;39:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId>
            <ArticleId IdType="pmc">PMC7135076</ArticleId>
            <ArticleId IdType="pubmed">32007143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi: 10.1056/NEJMoa2001316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId>
            <ArticleId IdType="pmc">PMC7121484</ArticleId>
            <ArticleId IdType="pubmed">31995857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId>
            <ArticleId IdType="pmc">PMC7042881</ArticleId>
            <ArticleId IdType="pubmed">32031570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi: 10.1038/s41586-020-2008-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId>
            <ArticleId IdType="pmc">PMC7094943</ArticleId>
            <ArticleId IdType="pubmed">32015508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: 10.1038/s41586-020-2012-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId>
            <ArticleId IdType="pmc">PMC7095418</ArticleId>
            <ArticleId IdType="pubmed">32015507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team  A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId>
            <ArticleId IdType="pmc">PMC7092803</ArticleId>
            <ArticleId IdType="pubmed">31978945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId>
            <ArticleId IdType="pmc">PMC7092819</ArticleId>
            <ArticleId IdType="pubmed">32109013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vetter P, Vu D1, L’Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of COVID-19. BMJ. 2020;369:m1470. doi: 10.1136/bmj.m1470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1470</ArticleId>
            <ArticleId IdType="pubmed">32303495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20(6):697–706. doi: 10.1016/S1473-3099(20)30200-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(20)30200-0</ArticleId>
            <ArticleId IdType="pmc">PMC7156120</ArticleId>
            <ArticleId IdType="pubmed">32224310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId>
            <ArticleId IdType="pmc">PMC7270627</ArticleId>
            <ArticleId IdType="pubmed">32171076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Santiago BI, Beltran T, Stuyver L, Chu CK, Schinazi RF. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. Antimicrob Agents Chemother. 2004;48(12):4636–4642. doi: 10.1128/AAC.48.12.4636-4642.2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.48.12.4636-4642.2004</ArticleId>
            <ArticleId IdType="pmc">PMC529212</ArticleId>
            <ArticleId IdType="pubmed">15561837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM, Kolykhalov AA. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. Antiviral Res. 2019;171:104597. doi: 10.1016/j.antiviral.2019.104597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.antiviral.2019.104597</ArticleId>
            <ArticleId IdType="pubmed">31494195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al.  Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348–e01319. doi: 10.1128/JVI.01348-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01348-19</ArticleId>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O, Nguyen XN, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov VE. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses. 2015;7(12):6233–6240. doi: 10.3390/v7122934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v7122934</ArticleId>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020;218:16–28. doi: 10.1016/j.trsl.2019.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2019.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, et al.  β-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol. 2018;92:e01965–e01917. doi: 10.1128/JVI.01965-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01965-17</ArticleId>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flavell RA, Sabo DL, Bandle EF, Weissmann C. Site-directed mutagenesis: generation of an extracistronic mutation in bacteriophage Q beta RNA. J Mol Biol. 1974;89(2):255–272. doi: 10.1016/0022-2836(74)90517-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-2836(74)90517-8</ArticleId>
            <ArticleId IdType="pubmed">4444051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullins JI, Heath L, Hughes JP, Kicha J, Styrchak S, Wong KG, Rao U, Hansen A, Harris KS, Laurent JP, Li D, Simpson JH, Essigmann JM, Loeb LA, Parkins J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One. 2011;6(1):e15135. doi: 10.1371/journal.pone.0015135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0015135</ArticleId>
            <ArticleId IdType="pmc">PMC3021505</ArticleId>
            <ArticleId IdType="pubmed">21264288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini ML, Andres EL, Sims AC, Rl G, Sheahan TP, Lu X, et al.  Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221–e00218. doi: 10.1128/mBio.00221-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.00221-18</ArticleId>
            <ArticleId IdType="pmc">PMC5844999</ArticleId>
            <ArticleId IdType="pubmed">29511076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter WP, Holman W, Bush JA, Almazedi F, Malik M, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chem. 2021;65(5). 10.1128/AAC.02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency (MHRA). Guidance: Clinical trials applications for Coronavirus (COVID-19). https://www.gov.uk/guidance/clinical-trials-applications-for-coronavirus-covid-19 (https://www.gov.uk/guidance/clinical-trials-applications-for-coronavirus-covid-19 published 19 March, 2020).</Citation>
        </Reference>
        <Reference>
          <Citation>MacKenzie R, Honig P, Sewards J, Goodwin R, Hellio MP. COVID-19 must catalyse changes to clinical development. Nat Rev Drug Disc. 2020;19(10):653–654. doi: 10.1038/d41573-020-00149-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41573-020-00149-2</ArticleId>
            <ArticleId IdType="pubmed">32884108</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
